Physician profile
Robin Lebo
NPI 1609444017
$6,248.26
in general payments reported to CMS, 2019-2025
37 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $1,548 · 2023: $1,626 · 2024: $1,549 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.04 | 2022-2025 | |
| Novo Nordisk INC | $815.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $767.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $578.93 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $469.77 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $316.26 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $276.64 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.95 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $210.24 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $203.82 | 2022 | |
| Glaxosmithkline, LLC. | $164.58 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Radius Health, INC. | $147.98 | 2021-2022 | |
| Exact Sciences Corporation | $121.16 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $109.50 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $108.03 | 2021-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $104.49 | 2024-2025 | Veozah |
| Organon LLC | $64.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $63.24 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $50.52 | 2022-2023 | Austedo Xr |
| Dexcom, INC. | $49.36 | 2024-2025 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $43.06 | 2022 | |
| Kyowa Kirin, INC. | $42.72 | 2023-2024 | Crysvita |
| Merck Sharp & Dohme LLC | $38.00 | 2022-2023 | Belsomra |
| Inspire Medical Systems, INC. | $36.53 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $32.50 | 2021 | |
| Novavax INC | $27.19 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Corcept Therapeutics | $26.30 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $23.36 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $21.37 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.65 | 2022 | |
| Harmony Biosciences LLC | $19.47 | 2025 | |
| Sanofi Pasteur INC. | $17.49 | 2023 | |
| Medtronic, INC. | $16.68 | 2025 | Inceptiv |
| Pharming Healthcare, INC. | $14.41 | 2022 | |
| Boston Scientific Corporation | $14.20 | 2023 | |
| Intercept Pharmaceuticals, INC. | $12.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Lebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.